Kornimate/medical-research-clean huggingface dataset:
spatial cognitive training for chronic vestibular disorders

Conditions: Vestibular Abnormality; Cognitive Training

Summary: in this study the investigators propose to apply cognitive training, which has been largely used in the realm of age-related cognitive decline, dementia, and alzheimer's disease, in a novel clinical context to individuals with vestibular impairment. in prior work the investigators observed that individuals with vestibular loss have evidence of spatial cognitive impairment. the investigators plan to evaluate the preliminary efficacy and feasibility of a cognitive training program in a sample of participants with chronic vestibular impairment who display deficits in spatial ability. the cognitive training program will focus on visuospatial skills and will be used as an adjunct to traditional vestibular physical therapy (vpt).

patients with chronic vestibular dysfunction with report symptoms of spatial cognitive impairment will be offered cognitive training. the intervention will consist of a well-validated cognitive training protocol that specifically targets spatial navigation skills. the protocol was developed by willis et al. for the adult development and enrichment trial (adept) trial, which trains map reading and route-learning skills through mental rotation training tasks over the course of 5 weeks. patients will be assessed by study staff pre-intervention, immediately post-intervention and at 3 months post-intervention using spatial cognitive outcomes, quality of life measures, and gait and balance outcomes.

Eligibility criteria:
inclusion criteria: * diagnosis of chronic vestibular disorder (\>6months \& diagnosis from laboratory testing by neuro-otologist) exclusion criteria: * participants with dementia, or with blindness or deafness who cannot participate in cognitive training procedures.
hormone estradiol replacement therapy additional herbals

Conditions: Menopause

Summary: the purpose of this study is to determine whether hormone replacement therapy (hrt), safety studies are combined with herbal (garlic oil, rutin, and nattokinase) to reduce estrogen side effects. making it safer when an endocrine supplement is needed for estrogen deficiency symptoms in menopausal and postmenopausal women.

recent studies have proved : -garlic oil as garlic may reduce platelet aggregation, patients taking anticoagulant medication are cautioned about consuming garlic. a 2013 meta-analysis concluded that garlic preparations may effectively lower total cholesterol by 11-23 mg/dl and ldl cholesterol by 3-15 mg/dl in adults with high cholesterol if taken for longer than two months. the same analysis found that garlic had a marginally positive effect on hdl cholesterol, no significant effect on blood triglyceride levels, and that garlic preparations were generally well tolerated with very few side effects. * nattokinase nattō is made from fermented soybeans and has been eaten in japan for about a thousand years. nattō is produced by fermentation by adding the bacterium bacillus natto to boiled soybeans. nattokinase is produced by the bacterium acting on the soybeans . while other soy foods contain enzymes, it is only the nattō preparation that contains the specific nattokinase enzyme. * estradiol valerate is one of the most widely used esters of estradiol. * progesterone: hormone replacement therapy. progesterone is combined with 17-beta estradiol in the estrogen patch.

Eligibility criteria:
inclusion criteria: * hormone replacement therapy (hrt) for oestrogen deficiency symptoms in perimenopausal and postmenopausal women. * prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. exclusion criteria: * known, past or suspected breast cancer; * known or suspected oestrogen-dependent malignant tumours (eg endometrial cancer); * undiagnosed genital bleeding; * untreated endometrial hyperplasia; * previous or current venous thromboembolism (deep venous thrombosis,pulmonary embolism) * known thrombophilic disorders (eg protein c, protein s, or antithrombin deficiency, see section. * active or recent arterial thromboembolic disease (eg angina, myocardial infarction); * acute liver disease, or a history of liver disease as long as liver function tests have failed to return to normal; * known hypersensitivity to the active substances or to any of the excipients;
efficacy and safety study of halneuron in the treatment of chemotherapy-induced neuropathic pain

Conditions: Chemotherapy Induced Neuropathic Pain

Summary: a randomized study to determine safety and efficacy of single subcutaneous (sc) administration of hal treatment in patients with cinp.


Eligibility criteria:
inclusion criteria: * male or female patients aged ≥18 years. * neuropathic pain has been present and is attributed to platinum and/or taxane chemotherapy. * patient has received a cancer chemotherapy regimen that included taxanes and/or platinum and has no active or discernible disease progression. exclusion criteria: * current neuropathic pain with symptoms similar to cinp but attributed to causes other than platinum or taxane chemotherapy. * patients who have received hal at any time prior to screening.

Keywords: neuropathic pain chemotherapy pain neuropathy cancer cipn cinp
sensor and software use for improved glucose control in mdi managed diabetes

Conditions: Diabetes Mellitus

Summary: to understand if multiple daily injections (mdi) managed subjects can improve glycaemic control by; 1. regularly checking and understanding continuous glucose data \& trend arrows at times other than the standard pre-meal bolus calculation test times and 2. review of their glucose profiles (inc. hypoglycaemic risks) with their health care professional (hcp) and adjusting behaviours \& therapy from interpretation of the continuous glucose profiles.


Eligibility criteria:
inclusion criteria: * age 18 years and over * type 1 diabetes on mdi with bolus injections for \>6 months prior to study enrolment or type 2 diabetes treated with 2 or more insulin injections daily. * in the investigator's opinion, thought technically capable of using freestyle navigator gm system device. * hba1c between 7.5 and 12.0% (58 to 108 mmol/mol) for previous test obtained within 6 months prior to point of enrolment exclusion criteria: * concomitant disease or condition that may compromise patient safety, including unstable coronary heart disease, cystic fibrosis, serious psychiatric disorder, or any uncontrolled chronic medical condition * female subject is pregnant or planning to become pregnant within the planned study duration. subjects who become pregnant during the study will be discontinued from the study. * currently using / has previously used a continuous glucose monitoring system within the last 6 months. * currently using continuous subcutaneous insulin infusion (csii) * currently using basal/long acting insulin only. * participating in another study of a glucose monitoring device / drug that could affect glucose measurements / management * known allergy to medical grade adhesives * in the investigators opinion is unsuitable to participate due to any other cause/reason.

Keywords: cgm mdi
use of the walant anesthesia technique for forefoot surgery.

Conditions: Orthopedic Disorder

Summary: to compare the perioperative pain level with walant anesthesia versus general anesthesia during forefoot surgery.

orthopaedic foot and ankle surgery is typically performed while the patient is under general or regional anesthesia. the wide awake local anesthesia no tourniquet (walant) technique is a local anesthesia technique used since 1980s in canada for hand surgery. walant uses a combination of a local anesthetic and vasoconstrictor to induce anesthesia and hemostasis in the area of the surgical procedure in order to allow surgeries to be done without the use of tourniquet. this practice eliminates the need for the tourniquet due to the hemostatic effect of the vasoconstrictor. the administration of the local anesthetic is done as close as possible to the surgical site, which allows the mobility of the joint to be maintained, while having complete anesthesia. the retention of mobility and the absence of a tourniquet improve patient comfort. the main objective of this prospective study is to evaluate the perioperative pain level with walant anesthesia compared to general anesthesia during forefoot surgery.

Eligibility criteria:
inclusion criteria: * patient, male or female, over 18 years of age * patient with scheduled forefoot surgery exclusion criteria: * protected patient : major under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision * pregnant or breastfeeding woman
weight-bearing magnetic resonance imaging (mri) for analysis of knee osteoarthritis (oa)

Conditions: Osteoarthritis

Summary: the purpose of the study is to use different x-ray and magnetic resonance (mr) imaging techniques to take pictures of the knee. there are two specific purposes to the study: 1. whether the different x-ray and mri techniques will give the same or different information about the knee joint and 2. which part of the knee joint will show the biggest change using the different x-ray and mri techniques. the study is not designed to test a hypothesis.


Eligibility criteria:
inclusion criteria: * female * 40 years and older * subjects who are willing and able to comply with x-ray and mri procedures * evidence of a personally signed and dated consent document additional inclusion for normal controls: * infrequent knee pain, aching, or stiffness during the past year or infrequent use of medication for treatment of knee pain during the past year * no evidence of oa on either knee (i.e. k-l grade = 0 diagnosed by knee radiography) additional inclusion for oa patients: * pain, aching, or stiffness on most days of a month during the past year; or use of medication for treatment of knee pain on most days of a month during the past year * kellgren-lawrence grade 2 or 3 of the study knee obtained on a standard knee radiograph (with either the same or less severe oa, or no oa in the contralateral knee) exclusion criteria: * subject is unable to undergo mri because of contraindication * women at risk of pregnancy * weight greater than 250 lbs * history of surgery in the study knee * history of other diseases involving the study knee joint including inflammatory joint diseases, crystalline disease, and infection of the study knee

Keywords: knee osteoarthritis magnetic resonance imaging x rays
oncologic therapy support via means of a dedicated mobile app

Conditions: Thoracic Neoplasm; Pelvic Neoplasm; Radiotherapy; Complications; Oncologic Disorders; Breast Cancer; Satisfaction; Quality of Life

Summary: the present single-center prospective exploratory study, conducted at heidelberg university hospital, assesses the feasibility of introducing a concept for additional patient care based on a mobile application for patients undergoing radiotherapy. patients presenting themselves for the irradiation of thoracic or pelvic tumors will be surveyed regarding general performance, treatment-related quality of life (qol) and symptoms and their need to personally consult a physician on a treatment-daily basis by means of a mobile application. the primary endpoint of feasibility will be reached when 80% of the patients have successfully answered 80% of their respective questions scheduled for each treatment day. furthermore, treatment-related patient satisfaction and diagnosis-related qol is assessed by psq-18 and eortc questionnaires at the end of radiotherapy and at the first follow-up.


Eligibility criteria:
inclusion criteria: * indication for radiotherapy with potentially curative intent of a primarily thoracic or pelvic target * karnofsky performance score (kps) ≥ 70%, * ability to initiate the therapy as an outpatient * ≥ 18 years of age exclusion criteria: * inability to give informed consent

Keywords: mobile application radiotherapy patient-care mhealth follow-up patient satisfaction quality of life
using boned-apatite cement at the time of extraction for ridge preservation at these sites

Conditions: Alveolar Bone Loss

Summary: to assess efficiency of ridge preservation (in vertical and horizontal dimensions) after tooth extraction using calcium sulfate with hydroxyapatite(®bond-apatite) compared to the use of bovine bone substitute (biooss®) and to extration only as negative control.

dental implants have become in the past ten years a popular and promising treatment in the rehabilitation of missing teeth. however, using implants depends on adequate alveolar bone volume. anatomical restrictions are mostly present in posterior mandibular and maxillary regions. alveolar bone loss usually occurs because of active periodontal disease, trauma or teeth extractions. teeth extractions are associated with some loss of alveolar bone in the horizontal and vertical dimensions. this loss is more pronounced when teeth are extracted because of periodontal disease. bone grafts from different origins (autogenic, allogenic, xenogenic or alloplastic) can partly reduce the alveolar bone loss. different ridge preservation techniques were succesfully used in clinical trials, using membranes only or as a combination of membranes and bone substitutes. synthetic bone grafts have been proven successfully for ridge preservation. calcium sulfate is the oldest material, being in use in dentistry for more than 30 years , and in orthopedics for more than 100 years . calcium sulfate is completely absorbed and constitutes a matrix on wich bone is able to grow (osteoconductive). it does not induce inflammation and doesn't alter calcium levels in the blood flow.previous studies has shown that calcium sulfate is completely replaced by bone. on the other hand, fast absorption of calcium sulfates can alter the dimensional stability of the graft. adding hydroxy appatite may improve stability during bone remodeling. this study includes patients who need extractions of incisors, canines or premolars. the extraction sockets must be mostly intact with a maximum 4 mm of one wall missing in the vertical dimension. 30 patients who need extractions from region of interest, with no extended bony defects, will be enrolled from the department of periodontology, school of graduate dentistry, rambam health care campus

Eligibility criteria:
inclusion criteria: * informed consent properly described and signed. * patients who need extractions of molars for dental or periodontal reasons. * at least 18 years old. * need for future dental implants in the extraction areas. exclusion criteria: * no informed consent. * pregnant women. * women who breastfeed. * patients treated with drugs influencing metabolism of bone such as bisphosphonates. * heavy smokers (more than 20 cigarettes per day). * patients with dentures pressing on the area of extractions/bone grafts

Keywords: extraction bond apatite
clinical findings in general paresis

Conditions: General Paresis

Summary: this is a study of the clinical and neuroimaging of general paresis. the investigators studied six patients with general paresis.

inclusion criteria: * mental disorders * positive tpha in csf and sera * hiv-negative serology by elisa exclusion criteria: * negative tpha in csf and sera * no image data

Eligibility criteria:
inclusion criteria: * eeg mr exclusion criteria: * serological test

Keywords: eeg general paresis mri neurosyphilis
effectiveness of ecoguided percutaneous neuromodulation of the multipurpose musculature of l-3 in non-specific chronic lumbar pain.

Conditions: Low Back Pain

Summary: the study evaluates the effectiveness of ultrasound-guided percutaneous neuromodulation in the lumbar multifidus of l3 in non-specific chronic low back pain.

the effectiveness of neuromoduation in analgesic therapies has been more than contrasted. considering that multifidus muscles, composed of the spinous transverse rotators muscles and spinous transverse multifidus muscles, are fundamental both for the static and for the dynamics of the lumbar spine, particularly for the region of l-3, the treatment of this musculature with ultrasound-guided percutaneous neuromodulation in patients with nonspecific chronic low back pain must have an analgesic repercussion in this nociceptive process. therefore, given that neuromodulation has been considered as a more than effective treatment in painful symptomatology and that diverse scientific literature has proven the activity of the multifida musculature directly affects the stability and mobility of the lumbar spine, it is more than likely interventions with neuromodulative treatments in the multifidus musculature at the level of the third lumbar vertebrae have positive results in non-specific chronic low back pain.

Eligibility criteria:
inclusion criteria: * score ≥4 on the roland morris disability questionnaire. * low back pain for ≥3 months * age between 18 and 65 years * not undergoing another physical therapy treatment exclusion criteria: * presence of lumbar stenosis * diagnosis of spondylolisthesis * diagnosis of fibromyalgia * treatment with corticosteroid or oral medication within the past two weeks * a history of spinal surgery * contraindication of analgesic electrical therapy * having previously received a treatment of electrical analgesia.

Keywords: neuromodulation low back pain ultrasound-guied percutaneous tens randomized controlled trial percutaneous stimulation
nutritional status and pharmacological treatment: impact on the toxicity and quality of life of patients with colorectal and breast cancer

Conditions: Nutritional Status; Colorectal Cancer; Breast Cancer

Summary: cancer patients undergo many different modalities of treatments. pharmacological treatment should be well understood. the nutritional status is not taken into account when calculating drug's doses and this may have an impact in toxicity and quality of life. the present study proposes to evaluate the relationship between the calculation of pharmacological treatment's doses, the toxicity and the impact on quality of life among colorectal and breast cancer's patients.

cancer patients undergo various treatment modalities depending on tumor type, location, disease staging, and overall clinical conditions. pharmacological treatments and surgeries are fundamental therapeutic strategies in many cases and are part of the daily routine of integrated cancer treatment services. the calculation of pharmacological doses often takes into account the patient's body surface area (bsa) or only weight, without however assessing their nutritional status as such. the surgical procedure, on the other hand, may expose the patient to an inflammatory response secondary to the operative trauma that requires immediate reaction of the diseased organism for an adequate recovery. in this sense, the objective of the present study is to evaluate the relationship between the calculated medication's doses and the nutritional status of patients submitted topharmacological treatment with neoadjuvant or adjuvant intention: patients candidates for surgery. different instruments will be used for nutritional assessment, as well as a questionnaire on quality of life, a specific criterion for evaluation of toxicities, laboratory tests and imaging. patients will be observed for 1 year and the data collected will allow the analysis of possible side effects and the impact on quality of life.

Eligibility criteria:
inclusion criteria: * pathological diagnosis of colorectal cancer or breast cancer * must have performance status to undergo surgery and pharmacological treatment (adjuvant or neoadjuvant treatment) exclusion criteria: * non-operable patients * pacientes with poor performance status eastern cooperative oncology group (ps ecog) \>2

Keywords: nutritional status colorectal cancer breast cancer pharmacological treatment toxicity quality of life
assessing function in pediatric patients with sickle cell disease

Conditions: Sickle Cell Disease

Summary: the purpose of this study is to evaluate the fim™ as a measure of daily function in children with sickle cell disease hospitalized with vasoocclusive pain. currently, the standard for pain assessment is a rating of pain intensity, as determined by observation (for younger children) or self-report (for older children and adolescents). however, these measures of pain intensity are not effective in recurrent or chronic pain states, and in sickle cell disease in particular. pediatric patients who are hospitalized with vasoocclusive pain often do not report a decrease in pain intensity; however, other indications of clinical status, such as ambulation, less use of opiates from the patient-controlled analgesia (pca) pump, increased food intake, and transition to oral pain medication, signify that the patient may be improving. as a result of our inability to get an accurate picture of the patients' condition, we would like to have a summary of improvement that would reflect these changes in clinical status and reflect the reduced impact of sickle cell pain on the patient's life. in this study, we plan to evaluate a standardized functional assessment measure in pediatric patients with sickle cell disease. it is hypothesized that fim™ scores will correlate with other indicators of clinical status, such as movement, quality of sleep, use of iv opiates from the patient-controlled analgesia (pca) pump, and use of intravenous vs. oral pain medications. it is also hypothesized that the fim™ will demonstrate adequate responsiveness to change in functional status within a 3-7 day hospitalization by a progressive increase in scores and associations with other indicators of clinical improvement.


Eligibility criteria:
inclusion criteria: * ages 7-21 years inclusive * documented sickle cell disease * sudden onset of pain consistent with vasoocclusive episode * pain requiring hospitalization and placement on standard clinical guideline for management of acute pain in sickle cell disease * cognitive ability to report pain on a 0-10 numerical rating scale (nrs) * parental consent and child assent exclusion criteria: * younger than 7 years old * primary diagnosis other than vasoocclusive pain * concurrent acute chest syndrome (acs)